Research programme: phytocannabinoid-based therapeutics - India Globalization Capital

Drug Profile

Research programme: phytocannabinoid-based therapeutics - India Globalization Capital

Alternative Names: Hyalolex; IGC-501; IGC-503; IGC-504; IGC-506; IGC-AD1; IGCADI; Serosapse

Latest Information Update: 12 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator India Globalization Capital
  • Class Analgesics; Antidementias; Antiparkinsonians; Cannabinoids
  • Mechanism of Action Cannabinoid receptor CB1 modulators; Cannabinoid receptor CB2 modulators; G protein-coupled receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Alzheimer's disease; Cachexia; Cancer pain; Eating disorders; Epilepsy; Neuropathic pain; Parkinson's disease; Post-traumatic stress disorders

Most Recent Events

  • 10 Apr 2018 India Globalization Capital files for patent protection with United States Patent and Trademark Office for IGC 507 in USA
  • 20 Feb 2018 Preclinical trials in Parkinson's disease in USA (unspecified route) before February 2018
  • 02 Jan 2018 Pharmacodynamics data from preclinical studies in Alzheimer's disease released by Indian Globalization Capital
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top